Table 2.
aHR for Nonfatal or fatal MACE.
| Variables | Nonfatal MACE | Fatal MACE | ||
|---|---|---|---|---|
| aHR (95% C.I.) | p | aHR (95% C.I.) | p | |
| Adjuvant therapy, ref: H group | ||||
| CH group | 0.622 (0.459–0.843) | 0.002 | 0.883 (0.689–1.131) | 0.330 |
| RH group | 0.831 (0.593–1.164) | 0.286 | 0.609 (0.430–0.862) | 0.005 |
| CRH group | 0.749 (0.548–1.024) | 0.070 | 0.712 (0.545–0.932) | 0.013 |
| Type of Hormone, ref: Anti-estrogens | ||||
| Aromatase inhibitors | 0.767 (0.517–1.138) | 0.189 | 1.023 (0.736–1.420) | 0.900 |
| Both | 1.279 (0.935–1.750) | 0.124 | 1.749 (1.371–2.231) | <0.001 |
| Age, ref: <45 | ||||
| 45–59 | 1.777 (1.179–2.679) | 0.006 | 1.097 (0.859–1.401) | 0.467 |
| >=60 | 4.795 (3.094–7.430) | <0.001 | 1.854 (1.383–2.486) | <0.001 |
| Laterality, ref: Right | ||||
| Left | 0.953 (0.769–1.180) | 0.672 | 1.074 (0.904–1.275) | 0.424 |
| Pathological stage, ref: 1 | ||||
| 2 | 1.041 (0.739–1.467) | 0.830 | 1.321 (0.999–1.746) | 0.050 |
| Tumour size (cm), ref: <2 | ||||
| 2–4 | 1.299 (0.933–1.808) | 0.121 | 1.673 (1.285–2.178) | <0.001 |
| >=4 | 1.380 (0.826–2.305) | 0.221 | 2.648 (1.871–3.749) | <0.001 |
| Co-morbidities | ||||
| Valvular heart disease | 1.519 (0.896–2.575) | 0.121 | 0.893 (0.502–1.591) | 0.714 |
| Hypertension | 2.140 (1.667–2.748) | <0.001 | 1.307 (1.058–1.615) | 0.013 |
| Diabetes mellitus | 1.586 (1.211–2.077) | 0.001 | 1.509 (1.179–1.931) | 0.001 |
| Hyperlipidemia | 0.831 (0.637–1.084) | 0.173 | 0.720 (0.562–0.923) | 0.009 |
| Abnormal liver function | 0.990 (0.750–1.307) | 0.948 | 1.021 (0.815–1.279) | 0.867 |
| Peptic ulcer | 1.026 (0.769–1.369) | 0.871 | 1.003 (0.784–1.283) | 0.983 |
| Abnormal renal function | 2.476 (1.585–3.868) | <0.001 | 2.393 (1.583–3.618) | <0.001 |
| COPD | 1.140 (0.727–1.788) | 0.580 | 0.917 (0.595–1.413) | 0.708 |
| Mental disorder | 1.463 (1.161–1.843) | 0.001 | 1.131 (0.929–1.376) | 0.221 |
| Rheumatic disease | 1.378 (0.864–2.199) | 0.179 | 1.321 (0.881–1.980) | 0.179 |
| Thyroid disorder | 1.023 (0.686–1.523) | 0.918 | 1.049 (0.752–1.463) | 0.791 |
| Osteoporosis | 0.688 (0.429–1.102) | 0.120 | 1.050 (0.727–1.516) | 0.807 |
aHR: adjusted hazard ratio; MACE: major cardiovascular events, COPD: chronic obstructive pulmonary disease, H group: hormone therapy alone; CH group: chemotherapy and hormone therapy; RH group: radiotherapy and hormone therapy; CRH group: chemotherapy, radiotherapy and hormone therapy. aHR adjusted for adjuvant therapy for breast cancer, type of hormone therapy, age group, lateral of cancer, pathological stage, tumour size and co-morbidities.